Prof Jean Abraham speaks to ecancer about the phase 3 PARTNER trial.

This trial examines olaparib's effects on wild-type and hereditary breast cancer patients, revealing that it does not improve outcomes for the wild-type group.

In contrast, the hereditary cohort shows improved event-free and overall survival, but no improvement in pathological complete response. The trial was stopped at a planned interim analysis timepoint.

Significant survival rate differences between treatment arms spark discussions on personalised treatment for hereditary breast cancer, with future studies planned to confirm these results and optimise strategies.